0001104659-22-068656.txt : 20220606
0001104659-22-068656.hdr.sgml : 20220606
20220606192923
ACCESSION NUMBER: 0001104659-22-068656
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220606
FILED AS OF DATE: 20220606
DATE AS OF CHANGE: 20220606
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BLOCH KATHLEEN P.
CENTRAL INDEX KEY: 0001409212
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36792
FILM NUMBER: 22999445
MAIL ADDRESS:
STREET 1: 3 PERSHING COURT
CITY: NORTH BRUNSWICK
STATE: NJ
ZIP: 08902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cytosorbents Corp
CENTRAL INDEX KEY: 0001175151
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 980373793
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 305 COLLEGE ROAD EAST
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 973-329-8885
MAIL ADDRESS:
STREET 1: 305 COLLEGE ROAD EAST
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER COMPANY:
FORMER CONFORMED NAME: MedaSorb Technologies CORP
DATE OF NAME CHANGE: 20060807
FORMER COMPANY:
FORMER CONFORMED NAME: GILDER ENTERPRISES INC
DATE OF NAME CHANGE: 20020611
4
1
tm2217836-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-06-06
0
0001175151
Cytosorbents Corp
CTSO
0001409212
BLOCH KATHLEEN P.
C/O CYTOSORBENTS CORPORATION
7 DEER PARK DRIVE, SUITE K
MONMOUTH JUNCTION
NJ
08852
0
1
0
0
Chief Financial Officer
Common Stock
2022-06-06
4
P
0
8700
1.8999
A
33700
I
See Footnote
Common Stock
349661
D
Includes (i) 10,000 shares held by the Reporting Person's husband in a 401(k) account, (ii) 15,000 shares held by the Reporting Person's husband in an IRA account and (iii) 8,700 shares held by the Reporting Person's husband in a ROTH IRA account and reported on this Form 4. The Reporting Person may be deemed the beneficial owner of such shares.
Includes: (i) the following RSUs that will be settled into common stock, par value $0.001 per share (the "Common Stock") upon a "Change In Control" of CytoSorbents Corporation (the "Company"), as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 8,800 RSUs granted on March 15, 2018, (b) 15,700 RSUs granted on February 24, 2017, (c) 47,000 RSUs granted on June 7, 2016 and (d) 110,000 RSUs granted on April 8, 2015;
(continued from footnote 2) (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date), and will be settled into common stock of the Company upon vesting: (a) 16,484 RSUs granted on April 12, 2021 and unvested as of the date hereof; and
(continued from footnote 3) (iii) 151,677 shares of Common Stock owned by the Reporting Person.
/s/ Kathleen P. Bloch
2022-06-06